Agalsidase-Beta Therapy for Advanced Fabry DiseaseMaryam Banikazemi, Robert J. Desnick, Jan Bultas et al.|Annals of Internal Medicine|2007Cited by 565
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyRaphael Schiffmann, Robert J. Desnick, David G. Warnock et al.|Nephrology Dialysis Transplantation|2009Cited by 366
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Joel Charrow et al.|Journal of Medical Genetics|2015Cited by 363
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortíz, David G. Warnock, Manesh R. Patel et al.|Journal of Medical Genetics|2016Cited by 147
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroupDominique P. Germain, David G. Warnock, João Paulo Oliveira et al.|Journal of Medical Genetics|2020Cited by 66